Overview
Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize treatment of genetically driven disease. Founded by the world’s foremost experts in epigenetic editing and protein engineering and backed by industry-leading investors, Chroma is positioned to be the leader in epigenetic editing.
Chroma is working at the cutting edge of precision genomics, building an entirely new class of therapeutics that can precisely and durably control gene expression without changing or cutting the underlying DNA sequence.